TITLE:
Biological Profile of People Living with HIV under Antiretroviral Therapy at the Ambulatory Treatment Center in Dakar, Senegal
AUTHORS:
Mouhamadou Thiam, Souleymane Thiam, Ndeye Fatou Ngom, Abdou Faye, Harouna Ousmane Sow, Amath Faye, Betty Fall, Alassane Ndiaye, Ibrahima Diao, Pape Matar Kandji, Ahmadou Mboup, Fatou Cissé, Moussa Seydi
KEYWORDS:
Biological Profile, Antiretroviral, PLHIV
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.17 No.3,
March
31,
2026
ABSTRACT: Introduction: Human immunodeficiency virus (HIV) infection remains a public health problem despite the advent of antiretroviral therapy (ART). Prolonged use of ART has been associated with various metabolic toxicities. This study aims to evaluate biological parameters in patients living with HIV who are receiving treatment at the Ambulatory Treatment Center (CTA). Methodology: This was a retrospective, descriptive, and analytical study conducted between January 2021 and December 2024, a period of three years. The study included all patients living with HIV who were followed at the CTA of the Fann University Hospital Center and had undergone biological testing. Results: During the study period, 163 patients were included, with a mean age of 38 years ± 11.94. We noted a male predominance (92 men and 71 women, for a male-to-female ratio of 1.3). From a virological standpoint, HIV-1 was the most frequent, accounting for 93.3% of cases. TLD remained the predominant treatment regimen at the time of the study, used in 91.4% of cases, followed by TAF + FTC + DTG (5.6%). At month 36, 70% of patients had normal hemoglobin levels, and anemia had decreased to 27.1%. Renal function remained generally preserved, with an eGFR > 90 mL/min/1.73m2 in 65.3% of patients. Transaminase levels improved significantly, with a decrease in elevated AST and ALT. Viral load, mostly detectable at baseline (M0), became undetectable in more than 90.9% of patients by month 12 and remained so until month 36. Conclusion: The results confirm the efficacy and tolerability of antiretroviral therapy. Regular laboratory monitoring allows for the early detection of potential metabolic complications.